Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

September 29, 2009; 73 (13) Patient Page

Juvenile myoclonic epilepsy, a common epilepsy syndrome

Steven Karceski
First published September 28, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181bd13f1
Steven Karceski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Juvenile myoclonic epilepsy, a common epilepsy syndrome
Steven Karceski
Neurology Sep 2009, 73 (13) e64-e67; DOI: 10.1212/WNL.0b013e3181bd13f1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2027

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

WHAT WAS THE STUDY ABOUT?

In their article “Juvenile myoclonic epilepsy 25 years after seizure onset: A population-based study” (Neurology 2009;73:1041–1045), Drs. Camfield and Camfield studied something that has never been evaluated: how a group of people with this kind of epilepsy do over a long period of time. On the surface, it seems that it would be easy to identify a group of people, follow them for a long time, and then describe what happened to them. However, in our modern world, where people move frequently and sometimes over long distances, long-term studies can be very hard—if not impossible—to do.

Working in Nova Scotia, Drs. Camfield and Camfield identified people with JME. They looked carefully at their medical records to be certain that the group did not have another kind of epilepsy. For instance, the people could have had a generalized tonic-clonic seizure, but mainly were experiencing myoclonic seizures. Medical testing, such as an electroencephalogram (EEG), had to show the kind of abnormality that occurs in this kind of epilepsy (called a 3-hertz spike-and-wave pattern). Of course, the history, such as the age at onset, and a possible family history of epilepsy was carefully reviewed.

After all of these conditions were met, Drs. Camfield and Camfield had identified 24 people with JME. To find this group, the doctors reviewed the medical records of anyone who had been diagnosed with epilepsy between 1977 and 1985. Remember, they wanted to see how these people were going to do over 25 years, so they had to look back to the 1970s and 1980s to find people who would have had epilepsy for that period of time. They narrowed the group to only those with JME, using the criteria above.

All of the case files were reassessed between 2007 and 2008. The doctors also called the 24 people and asked them questions over the telephone. In this way, they were able to confirm what the records said and were able to make sure that there were no errors. The questions were posed in a formal interview style, and everyone was asked the same questions in the same way to make sure that the results were free from any biases. The doctors asked how well the group had done in school, whether they had a job, whether or not they had been married, and whether or not they had children. The reason for these personal questions was to determine if the epilepsy might affect whether or not a person could finish school, get a job, and maintain a relationship.

WHO WERE THE PARTICIPANTS?

The entire group had generalized tonic-clonic and myoclonic seizures (remember, this was one of the criteria they used to make the diagnosis). All of the people had been treated with antiseizure medications. Eight of the 24 (35%) had a serious kind of seizure called status epilepticus—this is a medical emergency. Three of the 24 (about 12%) had seizures that did not respond well to medications.

The other 88% had seizures that either responded to medications or went away on their own. More specifically, 17% were taking no medications and were not having seizures of any kind 25 years after the diagnosis of JME was made. Thirteen percent were taking no medication and had only myoclonic seizures. Since myoclonic seizures are very brief (see table 1), lasting only part of 1 second, most people experience no problems when these occur. Furthermore, the myoclonic seizures tend to occur in the early morning, within the first few hours of waking up. In other words, people with JME do not usually have their myoclonic seizures all day long.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Types of generalized seizures

After 25 years, about three-quarters (65%–77%) reported that they were “very satisfied” with their health, friendships, and social life; 87% were high school graduates, and 70% had gone on to higher education; 69% were currently employed “with enough income to be self-sufficient”; 9 people were taking medication for depression or anxiety, common problems that affect many people with epilepsy.

The authors acknowledge that the number of people in their study is small. Because of the small size of the group, they were unable to study what factors might help doctors to predict which person will become seizure-free. This finding is in direct opposition to what many earlier papers had said: that the seizures in JME never go away on their own.

WHY IS THIS STUDY IMPORTANT?

Doctors use many different kinds of studies to make decisions about the best way to counsel patients about their illness. Some studies demonstrate the effectiveness and safety of a specific treatment. Others might highlight certain problems that a treatment may cause. Using studies like the one by Drs. Camfield and Camfield, doctors will have a better understanding of what to expect over a long time. This can have clear implications for how they treat their patients. For instance, how long is treatment needed? When can treatment be stopped? What things in a person’s history or on medical testing will help me to decide if I should stop treatment? As of now, we have answers to only some of these questions. However, as research continues, we may begin to answer the remainder.

About juvenile myoclonic epilepsy

WHAT IS JME?

JME stands for juvenile myoclonic epilepsy. The name of the illness describes it well. JME is a kind of epilepsy that starts in adolescence (in other words, juvenile). In JME, the main kind of seizure that a person experiences is a myoclonic seizure. These are very brief, often described as “split-second” seizures that cause jerks of the arms more than the legs. Often, myoclonic seizures happen when people first wake up, causing them to drop their toothbrush, or drop the shampoo bottle (if they happen to shower first thing in the morning).

However, people with JME can have more than one kind of seizure. Often, they will experience generalized tonic-clonic seizures as well, though these usually occur less often than the myoclonic seizures (table 1). Generalized tonic-clonic seizures begin with stiffening, which is followed by shaking of both arms and legs. A person is unconscious during these, and the seizure might cause the person to fall and become injured. It is common for a person to visit a doctor after a tonic-clonic seizure. In fact, a person with myoclonic seizures could easily dismiss them because they are so brief. It is only after the “bigger” seizure that the “smaller” ones are discovered; however, when this combination of seizures occurs, starting in adolescence, the diagnosis is clear.

WHAT CAUSES JME?

The cause of JME is genetic, and up to one-half of people who have JME can identify other family members with the same illness. However, not everyone with JME knows someone in their family who has seizures. A person can have the gene, but never have seizures. Another way of thinking about this is that some people are “carriers” of the gene—for them, the gene is “silent.” However, they can still pass the gene to their children. Their children may (or may not) ever show the gene, meaning that many people in a family could have the gene, but only a few of them will have seizures. So far, several different genes have been identified as possible causes for JME.

WHO DEVELOPS JME?

JME can begin between the ages of 6 and 36, though for most people the seizures begin between the ages of 12 and 18. Why JME starts in adolescence is unclear, though some have proposed that the “trigger” is hormones. The reason for this is that the onset of the seizures coincides (for most people) with the physical changes that occur in puberty: hair growth, voice changes in men, and breast enlargement in women.

HOW IS JME DIAGNOSED?

As part of the evaluation for seizures, a doctor will order an electroencephalogram (EEG). This is a test that measures brain waves. When a person has seizures, his or her brain waves may show certain patterns. Although these patterns are not seizures, they are markers of seizures. In JME, a specific EEG pattern often occurs. It is called a “3-hertz spike-and-wave” which describes what it looks like when the EEG is reviewed.

HOW IS JME TREATED?

The main treatment of seizures is medication. Today, many medications are available for the seizures that occur in JME (table 2). In JME, the seizures usually respond to low doses of medication. Since side effects occur more often at high doses of medications, this means that most people with JME will experience good seizure control without side effects. However, a person with JME also needs to avoid triggers for seizures by getting plenty of rest and avoiding overindulgence in alcohol.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 An overview of treatment options for generalized seizures

In short, JME is a genetic epilepsy that causes seizures which begin in adolescence. Although people with JME may experience three kinds of seizures (generalized tonic-clonic, myoclonic, and absence), the one that they have most often is myoclonic. Most people with JME will stop having seizures if they take medications and avoid seizure triggers. Although doctors used to think that JME was life-long, studies like the one by Camfield and Camfield say otherwise: that up to one-third of people with JME may either be seizure-free or have myoclonic seizures only. In other words, life-long medication may not be needed. However, more study is required before doctors can predict which people with JME become seizure-free, and who might need lifelong medication.

FOR MORE INFORMATION

The Brain Matters

http://www.thebrainmatters.org

Epilepsy Foundation

http://www.epilepsyfoundation.org/

View Abstract

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • WHAT WAS THE STUDY ABOUT?
    • WHO WERE THE PARTICIPANTS?
    • WHY IS THIS STUDY IMPORTANT?
    • About juvenile myoclonic epilepsy
    • WHAT IS JME?
    • WHAT CAUSES JME?
    • WHO DEVELOPS JME?
    • HOW IS JME DIAGNOSED?
    • HOW IS JME TREATED?
    • FOR MORE INFORMATION
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (2)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise